Pfenex (PFNX) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Pfenex to Regain Full Rights to PF582 and Announces Phase 1/2 Results
August 8, 2016 7:30 AM EDTSAN DIEGO, Aug. 8, 2016 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that the company will regain the full rights to PF582, a biosimilar candidate to Lucentis®, following our partner's strategic review of the current therapeutic focus of its biosimilar pipeline.
"With Pfenex regaining the rights to PF582 we are announcing the PF582 phase 1/2 safety and efficacy data which we believe highlights the significant value of the program," stated Bertrand C. Liang, chief executive officer of Pfenex. "We will consider strategic options for PF582 following the expeditious transition of the... More
Pfenex Announces Positive Anthrax Vaccine Study Results
August 8, 2016 7:30 AM EDTSAN DIEGO, Aug. 8, 2016 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today positive immunogenicity and safety data from the Day 70 analysis of the Px563L anthrax vaccine study. The results demonstrate tolerable safety and significant immunogenicity after only 2 doses of Px563L.
"The Px563L data from the Day 70 analysis of the phase 1 study are very encouraging, with the vaccine being well-tolerated and affording potentially superior protection after only 2 doses," noted Dr. Hubert Chen, chief medical officer of Pfenex. Bertrand C. Liang, chief executive officer added, "These positive anthrax... More
Pfenex Reports Second Quarter 2016 Results and Provides Business Update
August 8, 2016 7:30 AM EDTSAN DIEGO, Aug. 8, 2016 /PRNewswire/ --Â Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the second quarter ended June 30, 2016 and provided a business update.
Pfenex disclosed today in a separate press release that the company will be regaining the full rights to PF582, a biosimilar candidate to Lucentis (ranibizumab), based on our collaboration partner's strategic review of the current... More
